Program: East Asian LCVL 2023 - Korean Language

Article and Video CATEGORIES

Cancer Journey

ABOUT

Dr. Chul Kim is an Associate Professor at Georgetown University focusing on thoracic oncology. His goal as a thoracic medical oncologist is to introduce innovative cancer therapies into clinical practice, and he is devoted to formulating clinical trials aimed at promoting personalized cancer treatments.

Program: East Asian LCVL 2023 - Korean Language

AlexandraGBeneke

Tue, 08/13/2024 - 08:36

English: Oncologists speak on topics in lung cancer, including risk factors, targeted therapy options, and the importance of genetic testing.

Korean: 종양학자들은 위험 요인, 표적 치료 옵션, 유전자 검사의 중요성 등 폐암 관련 주제에 대해 강연합니다.

Author

Chul Kim, MD - Guest Faculty

In this video series, Dr. Chul Kim translates discussions on lung cancer in Korean. Videos include information on SCLC and NSCLC including statistics and risk factors.

To watch the full playlist click here.

Video Language

Mandarin

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.